Showing results (131-140 of 208) with videos related to
Sort By:
Pageof 21
Nature Medicine|October 16, 2023
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.The Lancet. Oncology|February 7, 2017
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trialCorneel Coens, Stefan Suciu, Vanna Chiarion-Sileni, et al.Journal for Immunotherapy of Cancer|March 14, 2024
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trialDirk Schadendorf, Jason John Luke, Paolo A Ascierto, et al.The New England Journal of Medicine|June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanomaCaroline Robert, Luc Thomas, Igor Bondarenko, et al.NEJM Evidence|February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced MelanomaGeorgina V Long, F Stephen Hodi, Evan J Lipson, et al.European Journal of Cancer (Oxford, England : 1990)|May 30, 2020
Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trialAlexander M M Eggermont, Piotr Rutkowski, Caroline Dutriaux, et al.European Journal of Cancer (Oxford, England : 1990)|December 24, 2019
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.The Lancet. Oncology|April 5, 2015
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialAlexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Health-related quality of life results from the phase III CheckMate 067 studyDirk Schadendorf, James Larkin, Jedd Wolchok, et al.Nature Medicine|January 8, 2025
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trialReinhard Dummer, Caroline Robert, Richard A Scolyer, et al.Pageof 21